Pharmicell Co., Ltd. (005690.KS)
KRW 8000.0
(0.63%)
KRW 8000.0
(0.63%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 950.99 Million KRW | -89.28% |
| 2022 | 8.87 Billion KRW | 16.59% |
| 2021 | 7.61 Billion KRW | 5.22% |
| 2020 | 7.23 Billion KRW | 268.38% |
| 2019 | 1.96 Billion KRW | 654.71% |
| 2018 | 260.17 Million KRW | 105.83% |
| 2017 | -4.45 Billion KRW | -139.01% |
| 2016 | -1.86 Billion KRW | 66.27% |
| 2015 | -5.53 Billion KRW | 34.28% |
| 2014 | -8.41 Billion KRW | -10.22% |
| 2013 | -7.63 Billion KRW | 45.58% |
| 2012 | -14.03 Billion KRW | 13.97% |
| 2011 | -16.31 Billion KRW | -77.47% |
| 2010 | -9.19 Billion KRW | -269.58% |
| 2009 | -2.48 Billion KRW | 25.54% |
| 2008 | -3.33 Billion KRW | -61.79% |
| 2007 | -2.06 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -2.05 Billion KRW | -1825.95% |
| 2024 Q2 | 2.23 Billion KRW | 208.77% |
| 2023 Q4 | -106.65 Million KRW | -120.8% |
| 2023 FY | 950.99 Million KRW | -89.28% |
| 2023 Q1 | 315 Million KRW | 140.23% |
| 2023 Q2 | 574.82 Million KRW | 82.48% |
| 2023 Q3 | 512.82 Million KRW | -10.79% |
| 2022 Q1 | 4.9 Billion KRW | 935.81% |
| 2022 Q2 | 1.75 Billion KRW | -64.27% |
| 2022 Q4 | -782.97 Million KRW | -126.15% |
| 2022 Q3 | 2.99 Billion KRW | 70.67% |
| 2022 FY | 8.87 Billion KRW | 16.59% |
| 2021 Q1 | 1.4 Billion KRW | 4.87% |
| 2021 Q3 | 3.39 Billion KRW | 0.21% |
| 2021 Q4 | -587.29 Million KRW | -117.27% |
| 2021 Q2 | 3.39 Billion KRW | 141.43% |
| 2021 FY | 7.61 Billion KRW | 5.22% |
| 2020 FY | 7.23 Billion KRW | 268.38% |
| 2020 Q3 | 1.24 Billion KRW | -68.03% |
| 2020 Q2 | 3.89 Billion KRW | 416.8% |
| 2020 Q4 | 1.34 Billion KRW | 7.64% |
| 2020 Q1 | 753.62 Million KRW | 63.54% |
| 2019 Q4 | 460.82 Million KRW | 268.99% |
| 2019 FY | 1.96 Billion KRW | 654.71% |
| 2019 Q1 | 856.45 Million KRW | -43.71% |
| 2019 Q2 | 918.99 Million KRW | 7.3% |
| 2019 Q3 | -272.69 Million KRW | -129.67% |
| 2018 FY | 260.17 Million KRW | 105.83% |
| 2018 Q3 | -248.77 Million KRW | 44.14% |
| 2018 Q2 | -445.37 Million KRW | 21.46% |
| 2018 Q1 | -567.06 Million KRW | 52.88% |
| 2018 Q4 | 1.52 Billion KRW | 711.56% |
| 2017 FY | -4.45 Billion KRW | -139.01% |
| 2017 Q2 | -1.7 Billion KRW | -91.05% |
| 2017 Q4 | -1.2 Billion KRW | -82.32% |
| 2017 Q3 | -660 Million KRW | 61.27% |
| 2017 Q1 | -891.91 Million KRW | -5.92% |
| 2016 Q1 | -479.76 Million KRW | 41.96% |
| 2016 Q3 | 227.92 Million KRW | 129.53% |
| 2016 FY | -1.86 Billion KRW | 66.27% |
| 2016 Q2 | -771.76 Million KRW | -60.86% |
| 2016 Q4 | -842.08 Million KRW | -469.45% |
| 2015 Q2 | -1.05 Billion KRW | 45.4% |
| 2015 Q4 | -826.62 Million KRW | 52.05% |
| 2015 FY | -5.53 Billion KRW | 34.28% |
| 2015 Q1 | -1.92 Billion KRW | -5.41% |
| 2015 Q3 | -1.72 Billion KRW | -63.72% |
| 2014 Q3 | -1.83 Billion KRW | 37.55% |
| 2014 FY | -8.41 Billion KRW | -10.22% |
| 2014 Q4 | -1.82 Billion KRW | 0.31% |
| 2014 Q2 | -2.93 Billion KRW | -47.01% |
| 2014 Q1 | -1.99 Billion KRW | 61.99% |
| 2013 Q2 | -2.42 Billion KRW | -113.97% |
| 2013 FY | -7.63 Billion KRW | 45.58% |
| 2013 Q4 | -5.25 Billion KRW | -566.52% |
| 2013 Q3 | 1.12 Billion KRW | 146.48% |
| 2013 Q1 | -1.13 Billion KRW | 75.04% |
| 2012 Q2 | -3.45 Billion KRW | -11.1% |
| 2012 Q1 | -3.11 Billion KRW | 0.0% |
| 2012 FY | -14.03 Billion KRW | 13.97% |
| 2012 Q4 | -4.54 Billion KRW | -64.86% |
| 2012 Q3 | -2.75 Billion KRW | 20.39% |
| 2011 Q4 | - KRW | 100.0% |
| 2011 FY | -16.31 Billion KRW | -77.47% |
| 2011 Q3 | -4.4 Billion KRW | -34.03% |
| 2011 Q1 | -1.94 Billion KRW | 53.2% |
| 2011 Q2 | -3.28 Billion KRW | -68.99% |
| 2010 Q2 | -1.91 Billion KRW | -36.27% |
| 2010 Q3 | -1.67 Billion KRW | 12.76% |
| 2010 Q4 | -4.15 Billion KRW | -148.34% |
| 2010 FY | -9.19 Billion KRW | -269.58% |
| 2010 Q1 | -1.4 Billion KRW | -256.5% |
| 2009 Q1 | -668.28 Million KRW | -239.33% |
| 2009 Q2 | 252.48 Million KRW | 137.78% |
| 2009 Q3 | -2.97 Billion KRW | -1276.72% |
| 2009 Q4 | 900.05 Million KRW | 130.29% |
| 2009 FY | -2.48 Billion KRW | 25.54% |
| 2008 Q1 | -1.04 Billion KRW | -33.74% |
| 2008 Q4 | 479.64 Million KRW | 117.32% |
| 2008 Q3 | -2.76 Billion KRW | -281.53% |
| 2008 Q2 | -725.68 Million KRW | 30.29% |
| 2008 FY | -3.33 Billion KRW | -61.79% |
| 2007 Q3 | -588.71 Million KRW | -153.07% |
| 2007 Q1 | -464.63 Million KRW | 0.0% |
| 2007 Q2 | -232.63 Million KRW | 49.93% |
| 2007 FY | -2.06 Billion KRW | 0.0% |
| 2007 Q4 | -778.34 Million KRW | -32.21% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ORIENT BIO Inc. | 1.45 Billion KRW | 34.541% |
| Green Cross Holdings Corporation | -16.43 Billion KRW | 105.785% |
| Green Cross Holdings Corporation | 34.43 Billion KRW | 97.238% |
| Green Cross Corporation | 34.43 Billion KRW | 97.238% |
| GeneOne Life Science, Inc. | -48.36 Billion KRW | 101.966% |
| Celltrion, Inc. | 651.43 Billion KRW | 99.854% |
| Samsung Biologics Co.,Ltd. | 1155.98 Billion KRW | 99.918% |
| SK bioscience Co.,Ltd. | -4.73 Billion KRW | 120.101% |
| SK Biopharmaceuticals Co., Ltd. | -37.52 Billion KRW | 102.534% |
| Prestige BioPharma Limited | -62.78 Billion KRW | 101.515% |